AstraZeneca and Daiichi Sankyo have secured FDA approval for a new first-line option in triple-negative breast cancer, according to the latest report. The antibody drug conjugate was developed through a broad collaboration between the companies. The approval expands the ADC pipeline into earlier-line care for patients with a “tough” TNBC subtype, reinforcing the role of ADCs as a platform for moving targeted oncology therapies forward in the treatment sequence. With this decision, AstraZeneca’s and Daiichi Sankyo’s collaboration continues to translate into regulatory milestones aimed at widening access to next-generation oncology mechanisms in earlier settings.